NCT04058496

Brief Summary

Cardiac surgery saves lives when patients suffer from cardiac disease. Local inflammation is important for tissue repair and wound healing after such an operation. Inflammation starts already when the patient is treated in the intensive care unit. When inflammatory proteins (cytokines) are released into the circulation, they cause also a systemic inflammation, which alerts the immune system of the body and activates defence mechanisms (=adaptive response). In some patients, systemic inflammation is out of control thereby causing organ dysfunctions, shock, and in the most severe cases even death (=maladaptive response). The aim of this study is to investigate the early phase of inflammation after the operation. Repeated blood samples will be taken of patients undergoing cardiac surgery to describe the patterns and dynamics of inflammation proteins. A better understanding of these mechanisms will potentially lead to improved treatment of patients after cardiac surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2018

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

June 21, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 15, 2019

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2022

Completed
Last Updated

July 21, 2022

Status Verified

July 1, 2022

Enrollment Period

3.4 years

First QC Date

June 21, 2019

Last Update Submit

July 18, 2022

Conditions

Keywords

Cardia surgeryCardio-pulmonary bypassInflammationWNTCytokines

Outcome Measures

Primary Outcomes (4)

  • Plasma concentration of Wnt5a (ng/ml)

    Measured by a commercially available ELISA

    Up to 48 hours after ICU admission

  • Plasma concentration of sFRP1 (ng/ml)

    Measured by a commercially available ELISA

    Up to 48 hours after ICU admission

  • Plasma concentration of sFRP5 (ng/ml)

    Measured by a commercially available ELISA

    Up to 48 hours after ICU admission

  • Plasma concentration of WIF-1 (pg/ml)

    Measured by a commercially available ELISA

    Up to 48 hours after ICU admission

Secondary Outcomes (3)

  • Daily fluid balance (ml)

    Up to 48 hours after ICU admission

  • Occurrence of complications (yes/no): composite endpoint of hemodynamic instability (defined as norepinephrine concentration = or > 0.1mcg/kg/min), delirium (defined as ICDSC score = or > 4), infections

    Up to 7 days after ICU admission

  • Length of ICU stay (days)

    Up to 4 weeks

Study Arms (3)

1

Coronary artery bypass surgery off-pump (n=24)

Other: Blood sampling

2

Coronary artery bypass surgery on-pump (n=16)

Other: Blood sampling

3

Coronary artery bypass surgery plus valve surgery (n=20)

Other: Blood sampling

Interventions

Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission

123

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients after open cardiac surgery

You may qualify if:

  • Cardiac surgery via sternotomy
  • Coronary-bypass bypass surgery with or without valve surgery
  • Postoperative hospitalisation in the cardio-surgical ICU
  • Available informed consent

You may not qualify if:

  • Preoperative infections (e.g. endocarditis)
  • Preoperative use of steroids or other immunosuppression

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital

Zurich, Switzerland

Location

Related Publications (3)

  • Hauffe T, Kruger B, Bettex D, Rudiger A. Shock Management for Cardio-surgical ICU Patients - The Golden Hours. Card Fail Rev. 2015 Oct;1(2):75-82. doi: 10.15420/cfr.2015.1.2.75.

    PMID: 28785436BACKGROUND
  • Hauffe T, Kruger B, Bettex D, Rudiger A. Shock Management for Cardio-surgical Intensive Care Unit Patient: The Silver Days. Card Fail Rev. 2016 May;2(1):56-62. doi: 10.15420/cfr.2015:27:2.

    PMID: 28785454BACKGROUND
  • Kruger BD, Hofer GE, Rudiger A, Spahn GH, Braun J, Bettex D, Schoedon G, Spahn DR. Wingless-related integration site (WNT) signaling is activated during the inflammatory response upon cardiac surgery: A translational study. Front Cardiovasc Med. 2022 Nov 11;9:997350. doi: 10.3389/fcvm.2022.997350. eCollection 2022.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood

MeSH Terms

Conditions

Inflammation

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Alain Rudiger, MD

    University of Zurich

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof. Dr. med.

Study Record Dates

First Submitted

June 21, 2019

First Posted

August 15, 2019

Study Start

November 1, 2018

Primary Completion

April 1, 2022

Study Completion

April 1, 2022

Last Updated

July 21, 2022

Record last verified: 2022-07

Locations